JFS Wealth Advisors’s ADMA Biologics ADMA Stock Holding History

JFS Wealth Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$372	Hold	37	–	–	﹤0.01%	1966
2026 Q2	$310	Sell	37 -41	-53%	-$374	﹤0.01%	2056
2026 Q1	$703	Buy	78 +6	+8%	+$95	﹤0.01%	1730
2025 Q4	$1.31K	Buy	72 +19	+36%	+$320	﹤0.01%	1657
2025 Q3	$777	Sell	53 -38	-42%	-$651	﹤0.01%	1677
2025 Q2	$1.66K	Buy	91 +18	+25%	+$367	﹤0.01%	1441
2025 Q1	$1.45K	Hold	73	–	–	﹤0.01%	1573
2024 Q4	$1.25K	Buy	73 +19	+35%	+$357	﹤0.01%	1630
2024 Q3	$1.08K	Buy	+54	New	+$840	﹤0.01%	1679

Other funds holding ADMA

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Ranger Investment Management Dallas, Texas $1.07B AUM 31.98% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Marathon Capital Management Hunt Valley, Maryland $488M AUM 28.5% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Bridge City Capital Lake Oswego, Oregon $480M AUM 47.16% 1-Year Est. Return

JFS Wealth Advisors's ADMA Position: Q3 2026 in Review

JFS Wealth Advisors held its ADMA Biologics (ADMA) position steady in Q3 2026 at 37 shares worth $372. The position accounts for ﹤0.01% of the portfolio, ranked #1966.

JFS Wealth Advisors first reported a position in ADMA in Q3 2024 and has held it in 9 quarters since. The position peaked at $1.66K in Q2 2025. 144 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

JFS Wealth Advisors held 37 shares of ADMA Biologics worth $372 as of Q3 2026.
JFS Wealth Advisors left its ADMA Biologics share count unchanged in Q3 2026.
ADMA Biologics made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q3 2026, its #1966 holding.
JFS Wealth Advisors first reported a position in ADMA Biologics in Q3 2024 and has held it in 9 quarters since.
JFS Wealth Advisors's ADMA Biologics position peaked at $1.66K in Q2 2025.
144 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on JFS Wealth Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.